Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies
Raffaella Franca, Stefania Braidotti, Gabriele Stocco, Giuliana Decorti
Abstract
INTRODUCTION: gene encode diminished activity enzyme, enhancing accumulation of active metabolites, and partially explaining the inter-individual differences in patients' clinical response. AREAS COVERED: variants in the prevention of severe thiopurine-induced hematological toxicities and the less known implication on TG-induced sinusoidal obstruction syndrome. Additional genetic and non-genetic factors impairing TPMT activity are considered. Literature search was done in PubMed for English articles published since1990, and on PharmGKB. EXPERT OPINION: subjects could be investigated to improve outcomes while avoiding risk of severe hepatotoxicity.
Topics & Concepts
Thiopurine methyltransferaseMercaptopurinePharmacogenomicsMedicinePharmacogeneticsGenotypingPharmacologyOncologyAzathioprineGeneInternal medicineGenotypeBiologyGeneticsDiseaseAcute Lymphoblastic Leukemia researchChildhood Cancer Survivors' Quality of LifeAdolescent and Pediatric Healthcare